Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERIPATEI walking rehabilitation program with one-off anti-inflammatory treatment for hip or knee osteoarthritis
2022-502018-10-00Phase 4Authorised
- Sponsor
- Centre Hospitalier Universitaire de Clermont-Ferrand
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Niflumic acid, ketoprofen, ibuprofen, diclofenac, acetaminophen and 4 more in primary coxarthrosis and knee osteoarthritis (OA), sponsored by Centre Hospitalier Universitaire de Clermont-Ferrand. Primary endpoint: Success of the therapeutic program. Planned start Nov 2023; status: authorised.
02
Drugs
Niflumic acidketoprofenibuprofendiclofenacacetaminophen
03
Conditions
primary coxarthrosisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2022-502018-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502018-10-00.